Search for content, post, videos

Nanoform and Boehringer Ingelheim execute master services agreement

handshake

The two companies have executed a master services agreement (MSA) to initiate projects in the pre-clinical early development space.

The aim with the agreement is to solve the challenge of poor bioavailability and solubility in new drug candidates.

“Wider uptake of the latest technological innovations is essential to address the low success rates for new drug candidates in pharma.”

“Wider uptake of the latest technological innovations is essential to address the low success rates for new drug candidates in pharma. We are delighted to collaborate with Boehringer Ingelheim to evaluate how our CESS platform can help more novel therapies reach the patients who need them. This is the first step toward what we hope will be a long and fruitful partnership between our companies,” says Christian Jones, CCO of Nanoform.

Photo: iStock